RT Journal Article
SR Electronic
T1 Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.11.21253399
DO 10.1101/2021.03.11.21253399
A1 Keity Souza Santos
A1 Jamille Ramos Oliveira
A1 Rafael Rahal G. Machado
A1 Helen Andrade Arcuri
A1 Jhosiene Yukari Magawa
A1 Isabela Pazotti Daher
A1 Alysson Henrique Urbanski
A1 Gabriela Justamante Händel Schmitz
A1 Roberto Carlos Vieira Silva, Júnior
A1 Edison Luiz Durigon
A1 Silvia Beatriz Boscardin
A1 Daniela Santoro Rosa
A1 Deborah Schechtman
A1 Helder I Nakaya
A1 Edecio Cunha-Neto
A1 Gabriele Gadermaier
A1 Verônica Coelho
A1 Jorge Kalil
A1 on behalf of COVID-19 SP-Brazil Team
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253399.abstract
AB Recent SARS-CoV-2 variants pose important concerns due to their higher transmissibility (1) and escape (2) from previous infections or vaccine-induced neutralizing antibodies (nAb). The receptor binding domain (RBD) of the Spike protein is a major nAb target (3), but data on its B cell epitopes are still lacking. Using a peptide microarray, we identified an immunodominant epitope (S415-429) recognized by 68% of sera from 71 convalescent Brazilians infected with the ancestral variant. In contrast with previous studies, we have identified a linear IgG and IgA antibody binding epitope within the RBD. IgG and IgA antibody levels for this epitope positively correlated with nAb titers, suggesting a potential target of antibody neutralizing activity. Interestingly, this immunodominant RBD region harbors the mutation hotspot site K417 present in P.1 (K417T) and B.1.351 (K417N) variants. In silico simulation analyses indicate impaired RBD binding to nAb in both variants and that a glycosylation in the B.1.351 417N could further hinder antibody binding as compared to the K417T mutation in P.1. This is in line with published data showing that nAb from either convalescents or anti-CoV-2 vaccinees are less effective towards B.1.351 than for P.1. Our data support the occurrence of immune pressure and selection involving this immunodominant epitope that may have critically contributed to the recent COVID-19 marked rise in Brazil and South Africa, and pinpoint a potential additional immune escape mechanism for SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by FAPESP project N. 2020/05256-7 and FINEP grant N. 01.20.0009.00.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by CAPPesq (Comissao de Etica Para Analise de Projetos de Pesquisa do HC-FMUSP) and CONEP (Comissao Nacional de Etica em Pesquisa) (CAAE: 30155220.3.0000.0068). All study participants signed informed consents.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data.